- Age ≥18 years
- Diagnosis of PV
- Willing and able to provide signed informed consent
- Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
- Under the supervision of a physician for the active management of PV, including but not limited to watchful waiting, ASA 81 mg or greater, antithrombotic therapy, PHL, HU, interferon (recombinant or pegylated busulfan), anagrelide
|
- Participation in an active clinical trial in which the study treatment is blinded
- Life expectancy <6 months
- Diagnosis of myelofibrosis (MF) (including primary MF or post-PV MF or post-essential thrombocythemia [ET] MF)
- Diagnosis of acute myelocytic leukemia (AML)
- Diagnosis of Myelodysplastic Syndrome
- History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
- Splenectomy
|